PucMed Is An All-Natural Cannabis Company That's Setting Its Roots In Uruguay

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Quality and health are at the forefront of importance for this cannabis company. 
 
Created by Alfonso Cardozo Ferretjans, MD, PucMed is a hemp cultivation company based in Uruguay. Ferretjans started the brand as a way to unite his two passions, agriculture and medicine. 
 
In August 2019, PucMed obtained its first license to grow cannabis and have already expanded its authorized area of cultivation from 5 to 50 thousand square meters. 
 

The Cannabis Market In Uruguay

Uruguay was the first country in the world to legalize marijuana. And as it stands, continues to be a great place for those interested in investing in cannabis. 
 
According to PucMed, production costs in Uruguay are around ¼ of those in the U.S. and Canada. The prices of the land, labor, licenses and tax deductions make Uruguay a competitive market.
 
Uruguay’s new government has decided to break a secular tradition of being a big meat exporter to make cannabis its main national product creating great potential for this market.
 

The Company’s Mission

PucMed is the only cultivator in Uruguay producing 100% organic and hydroponic CDB flowers. This feeds into the company’s mission to search for natural solutions to guarantee the quality of its products.
 
This past week, the company signed with a Canadian extraction lab that agreed to buy 100% of its production in 2021-2022.
 
“Uruguay can be the new cannabis El Dorado and we at PucMed have the know-how and the facilities ready to receive investments for the enlargement of our operation and deliver great returns,” said David Peixoto, partner at PucMed.
 
To learn more about the cannabis space and its leaders, you can sign up for Benzinga’s upcoming Virtual Cannabis Capital Conference by clicking here. 

Photo by Matteo Paganelli on Unsplash

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.